Form 8-K - Current report:
SEC Accession No. 0001013762-25-000595
Filing Date
2025-03-18
Accepted
2025-03-18 16:15:08
Documents
15
Period of Report
2025-03-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0234837-8k_enzobio.htm   iXBRL 8-K 23853
2 PRESS RELEASE OF ENZO BIOCHEM, INC. ISSUED ON MARCH 17, 2025 ea023483701ex99-1_enzo.htm EX-99.1 36545
3 GRAPHIC ex99-1_001.jpg GRAPHIC 17693
  Complete submission text file 0001013762-25-000595.txt   263403

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE enz-20250317.xsd EX-101.SCH 3000
5 XBRL LABEL FILE enz-20250317_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE enz-20250317_pre.xml EX-101.PRE 22350
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0234837-8k_enzobio_htm.xml XML 3561
Mailing Address ENZO BIOCHEM INC 60 EXECUTIVE BLVD FARMINGDALE NY 11735
Business Address 60 EXECUTIVE BLVD FARMINGDALE NY 11735 5167555500
ENZO BIOCHEM INC (Filer) CIK: 0000316253 (see all company filings)

EIN.: 132866202 | State of Incorp.: NY | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-09974 | Film No.: 25748498
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)